RESEARCH. Previous attempts to stop tumours from gaining access to new blood vessels have not been successful. But what if the blood vessels not only expand by branching out, but also by splitting lengthwise? The idea breathes new life into a 50-year-old idea in cancer research and offers hope of a better treatment for malignant melanoma, an aggressive form of cancer. Tumours need blood just as our organs do. As…
Flexible new method for early cancer diagnosis
RESEARCH. Earlier discovery of cancer and greater precision in the treatment process are the objectives of a new method developed by researchers at Sahlgrenska Academy and Boston University. Investments are now being made to roll out this innovation across healthcare and broaden the scope of the research in this field. “We can screen at-risk patient groups, and we also plan to spot the cancer patients who are relapsing so that…
Anna Rohlin wrote last year’s best dissertation
PRIZES. Tuesday May 17, Sahlgrenska Academy recognized seven dissertations that were defended at the faculty last year. Anna Rohlin, who received her PhD in clinical genetics, wrote the dissertation crowned the best dissertation of the year 2015. “There are many dissertations from the Sahlgrenska Academy every year, and it feels fantastic to be recognized like this,” said Anna Rohlin. Anna did her dissertation work in Margareta Nordling’s research group in…
The Assar Gabrielsson Award goes to Anna Staffas and Rebecka Arnsrud Godtman
AWARD. For the first time, the Assar Gabrielsson Foundation is dividing its award between two medical researchers. The winners, Anna Staffas and Rebecka Arnsrud Godtman, have carried out acclaimed cancer research within leukemia and prostate cancer screening, respectively. The award amount is SEK 100,000 per person. The Assar Gabrielsson Foundation aims to draw attention to both experimental and patient-based research. This is why, from this year on, two prizes will be…
Clinical development of modern cancer drugs get a boost from a forgotten drug candidate
MEDICAL ARCHEOLOGY. An old drug candidate, from the 1980s, can help new clinical trials find the right patient category for new cancer drugs. That was the conclusion of a researcher couple at Sahlgrenska Academy that dug through the medical literature and discovered a forgotten drug molecule. Work with a new molecule, called RVX2135, awakened interest in the discarded drug candidate. Researcher couple, Jonas and Lisa Nilsson, had shown that RVX2135…